A260 AGREEMENT BETWEEN COLONOSCOPY-DETECTED AND PATHOLOGY-CONFIRMED COLORECTAL CANCER IN THE 2012 TIANJIN COLORECTAL CANCER SCREENING PROGRAM

2012年天津市结直肠癌筛查项目中结肠镜检查发现与病理确诊的结直肠癌之间的A260协议

阅读:2

Abstract

BACKGROUND: The Tianjin Colorectal Cancer (CRC) Screening Program uses a questionnaire (HRFQ) to determine risk status and the initial screening test: stool testing (FIT) for average-risk and colonoscopy for high-risk individuals. AIMS: To determine agreement between colonoscopy-detected CRC and pathology-confirmed CRC. METHODS: A retrospective cohort study was conducted using the data from the 2012 Tianjin CRC Screening Program in Tianjin, China. Participants were aged 60 to 74 and residents of Tianjin who completed both the HRFQ and colonoscopy. Demographics and clinical data were obtained as well as FIT, colonoscopy and pathology results. Cohen’s Kappa was used to determine agreement between colonoscopy-detected and pathology-confirmed CRC. RESULTS: In 2012, 19,096 individuals completed the HRFQ and colonoscopy, of which 10,907 (57.1%) were HRFQ positive and 7,986 (41.8%) were colonoscopy positive. Colonoscopy positive findings included 7160 polyps, 728 adenomas and 102 CRC. Of all colonoscopy positive findings, 1,256 (15.7%) were sent to pathology where 326 were confirmed CRC. Only 59 (18.1%) of the pathology-confirmed CRC were detected at colonoscopy. Agreement between CRC detected at colonoscopy and CRC confirmed by pathology was Kappa=0.22 (95%CI=0.16–0.27). CONCLUSIONS: Poor agreement was found between colonoscopy-detected and pathology-confirmed CRC, suggesting that many CRCs are undetected and untreated. Effectiveness of the screening program would be improved by sending all removed tissues to pathology. FUNDING AGENCIES: Fonds de recherche du Québec- Santé

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。